For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Autolus Limited

USPTO Granted Patents = 58

% Expired Patents = 1.7

EPO Patents = 19

Trademarks = 3

Forward Citations = 64

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Martin Pulé (51 out of 72 patents)

Shaun Cordoba (36 out of 41 patents)

Simon Thomas (29 out of 29 patents)

4. Shimobi Onuoha (28 out of 33 patents)

5. Matteo Righi (11 out of 11 patents)

6. James Sillibourne (9 out of 9 patents)

7. Mathieu Ferrari (8 out of 8 patents)

8. Paul Maciocia (6 out of 8 patents)

9. Wen Chean Lim (5 out of 5 patents)

10. Biao Ma (5 out of 5 patents)

11. Ram Jha (4 out of 4 patents)

12. Evangelia Kokalaki (3 out of 3 patents)

13. Leila Mekkaoui (3 out of 7 patents)

14. Ekaterini Kotsopoulou (3 out of 3 patents)

15. John Anderson (2 out of 3 patents)

Core Competencies:

Chimeric Antigen Receptor

Cytokine Receptor

Engineered Immune Cells

CAR T-cells

Transgenic T-cell Receptor

Nucleic Acid Construct

Binding Domain

Retroviral Vectors

Lentiviral Vectors

Polypeptide

Signalling System

Cancer Treatment

58 patents: Sort by Forward Citations

1. 12655388 - VIRUS-LIKE PARTICLE (2026-06-16),

2. 12624088 - CHIMERIC RECEPTOR COMPRISING A LIGAND BINDING DOMAIN AND AN ENDODOMAIN COMPRISING A CYTOKINE RECEPTOR ENDODOMAIN AND AN INTRACELLULAR T CELL SIGNALLING DOMAIN (2026-05-12),

3. 12516119 - ANTI TRBC1 ANTIGEN BINDING DOMAINS (2026-01-06),

4. 12496314 - Antigen-Binding Domain (2025-12-16),

5. 12492410 - Engineered Cytolytic Immunecell (2025-12-09),

6. 12454578 - Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors (2025-10-28),

7. 12398194 - Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface (2025-08-26),

8. 12325733 - Binding domain (2025-06-10),

9. 12304942 - Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor (2025-05-20),

10. 12269860 - Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR (2025-04-08),

11. 12241124 - Molecular assessment of TRBC usage (2025-03-04),

12. 12241068 - CD79-specific chimeric antigen receptor (2025-03-04),

13. 12234295 - Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof (2025-02-25),

14. 12187769 - Cell (2025-01-07),

15. 12049510 - Chimeric antigen receptor (2024-07-30),

Company Overview

Autolus Limited is a biotechnology company based in London, specializing in the development of innovative therapies utilizing Chimeric Antigen Receptors (CARs). The company focuses on engineered immune cell therapies, particularly CAR T-cells, to target various cancers. Autolus is dedicated to advancing the field of immuno-oncology through its proprietary technologies, which include transgenic T-cell receptors and retroviral vectors, aiming to enhance the efficacy and safety of cancer treatments.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

58 Patents

#71 in London

#304 in United Kingdom

#12,380 in the World

London, United Kingdom

Autolus Limited

Forward Citations = 64

49 inventors:

Martin Pulé (51 out of 72 patents)

Shaun Cordoba (36 out of 41 patents)

Simon Thomas (29 out of 29 patents)

4. Shimobi Onuoha (28 out of 33 patents)

5. Matteo Righi (11 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Autolus Limited. Retrieved from https://idiyas.com/company/autolus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…